ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Brukinsa: Package Insert - Drugs.com
PDF) Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
Efficacy for BRUKINSA® (zanubrutinib) FL.
Brukinsa (Zanubrutinib) Approved by FDA for CLL and SLL
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma - ScienceDirect
Zanubrutinib for the Treatment of B-cell Malignancies - touchONCOLOGY
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma - ScienceDirect
Brukinsa: Package Insert - Drugs.com
BRUKINSA- zanubrutinib capsule, gelatin coated
Zanubrutinib: past, present, and future | Blood Cancer Journal
PDF) Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP | Srikumar Sahasranaman - Academia.edu
PDF) Zanubrutinib for the Treatment of B-cell Malignancies
Zanubrutinib: past, present, and future | Blood Cancer Journal
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies - ScienceDirect
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. - Abstract - Europe PMC
Zanubrutinib Wins in First-Line CLL for Older Patients | MedPage Today
Zanubrutinib: A review of its role in Mantle Cell Lymphoma | BLCTT
Head to head study design for BRUKINSA® (zanubrutinib) for WM.
Efficacy for BRUKINSA® (zanubrutinib) for CLL/SLL.
Zanubrutinib (BGB-3111, CAS Number: 1691249-45-2) | Cayman Chemical
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia | New England Journal of Medicine
